Global C-Reactive Protein (CRP) Testing Market - Forecasts from 2024 to 2029

Global C-Reactive Protein (CRP) Testing Market - Forecasts from 2024 to 2029

The C-Reactive Protein (CRP) testing market was valued at US$1.953 billion in 2022 and is expected to grow at a CAGR of 2.43% over the forecast period to reach a total market size of US$2.293 billion by 2029.

Tests for C-reactive protein (CRP) measure levels of this protein in the body. An increase in C-reactive protein levels in the body can be attributed to inflammation. The liver produces this protein. Inflammatory diseases and infections are identified and tracked by C-reactive protein tests, which include cancers, cardiovascular disease, arthritis, etc. The tests estimate whether someone is at risk of having a heart attack or stroke.

Cardiovascular diseases (CVDs) have become more prevalent, and as tests are becoming more complex, this market is being driven by these factors. As reported by the WHO, CVDs kill about 17.9 million people each year. Numerous opportunities exist in the market, including the growing application of these tests, point-of-care testing, increased population coverage, and increased healthcare awareness, particularly in developing countries.

The market is also expected to grow due to increased funds provided by the government to academic research institutions and individuals. Market growth is further anticipated to be supported by various initiatives by international organizations, including WHO and NIH, that aim to prevent and treat chronic disorders such as cancer and cardiovascular diseases.

Globally, the market for C-reactive protein tests will grow because of the rising prevalence of inflammatory disorders, the increasing prevalence of endometriosis in women, and technological advancements in diagnostic tests. A large number of chronic diseases, including lupus, ulcerative colitis, rheumatoid arthritis, and others, are thought to be triggered by chronic inflammation.

According to the Centers for Disease Control and Prevention (CDC) 2016 report, it is estimated that by 2040, approximately 78 million (26%) of US adults aged 18 and up will have arthritis. Furthermore, this market's growth would be challenged by the lack of public awareness.

Market Drivers:

An increase in cardiovascular disease is anticipated to surge the C-reactive protein (CRP) testing market growth.

It is urgently necessary to develop a quick and accurate method for diagnosing cardiovascular diseases, given their high prevalence. CRP can, therefore, be used to detect CVD due to the development of atherosclerosis, in which cholesterol is deposited inside blood vessel walls, leading to inflammation. As a result, CRP levels are higher in patients with cardiovascular disease.

Consequently, these CRP assays can detect low CRP levels, which are sensitive. Because cardiovascular diseases are increasingly prevalent, researchers are likely to pursue evaluations of CRP for cardiovascular disorders. According to the World Heart Federation, coronary heart disease is the leading cause of death in the world. There are an estimated 3.8 million males and 3.4 million females who die of coronary heart disease every year. More than 80% of deaths occur in low- and middle-income countries.

Additionally, approximately 356,000 cardiac arrests occur in the U.S. outside of hospitals every year, of which 90% are fatal, according to data from the American Heart Association 2019. It is for this reason that clinicians are increasingly implementing CRP testing. Hence, these factors combined are causing the cardiovascular diseases segment to grow at a steady pace over the forecast period.

Many research and development projects are conducted by universities and other organizations. For example, a group of researchers from the University of Hong Kong has developed a real-time, flexible sensing device that can directly measure CRP blood levels. With this sensor, inflammation testing is 30 times faster than usual. Incidents such as these are a major factor contributing to the C-reactive protein testing market growth.

Technological improvements in regular CRP tests are expected to propel the market growth.

Over time, CRP has developed into a flexible diagnostic tool for determining systemic inflammatory disorders. Advances in nanomaterials and electroanalytical chemistry have led to the creation of CRP tests with higher sensitivity and specificity. CRP testing has advanced to include CRP-based enzymatic tests using modern electrochemical biosensors, gradually replacing classical antigen-antibody interactions.

Electrochemical sensors are used in the development of a highly sensitive, portable detection system based on ZnS nanoparticles, metal-oxide-semiconductor field-effect transistor/bipolar junction transistor, aptamer, silicon nanowire, vertical flow immunoassay, field emission transmitter, and other nanomaterials.

Ultrasensitive CRP level analysis should be possible in much less time with future advancements in multidisciplinary approaches. Thus, CRP testing methods for diagnosing systemic inflammatory illnesses would be used by more individuals. New CRP identification chemicals and materials that facilitate the creation of sensing platforms also present a lot of prospects in the CRP testing market.

Market Restraints:

High cost and low public awareness could hinder market growth.

CRP testing instruments, however, are expensive. High costs will constrain the market during the given period. The lack of qualified professionals in the field will also hinder the market for CRP tests during the given period. In addition, low public awareness about the CRP test, as well as its low specificity in diagnosing a particular disease, are expected to restrain the market’s growth.

Key Developments:

November 2022- ProciseDx received FDA clearance for its ProciseDx instrument and C Reactive Protein (CRP) assay, which provides quantitative determination of CRP levels in patient serum in less than 5 minutes. The company expects FDA clearances for additional tests. ProciseDx has already obtained CE Marks and launched four gastroenterology tests in Europe, with 30 instruments installed and 50 sites working towards implementation. In the US, ProciseDx has submitted De Novo applications for two TDM tests, Procise IFX measures infliximab (Remicade® and biosimilars), and Procise ADL measures adalimumab (Humira® and biosimilars).
January 2022- LumiraDx, a next-generation point-of-care diagnostics company, achieved CE Marking for its C-reactive protein (CRP) Test. The test is a small, portable, fully automated microfluidic immunoassay that provides quantitative CRP determination within four minutes. It helps detect and evaluate infection and inflammation, with high CRP levels indicating antibiotic treatment in patients with respiratory infection symptoms, while normal or low CRP levels indicate viral or self-limiting infections that don't require antibiotics. It can be used at the patient's side in primary and community care, patient homes, and hospital emergency care settings.

Market Segmentation:

By Type
Immunoturbidimetric method
ELISA
Chemiluminescence
Spectrometry
By Application
Cardiovascular Diseases
Cancer
Rheumatoid Arthritis
Lupus
Others
By End Users
Hospitals and Clinics
Diagnostic Centres
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
South Korea
Taiwan
Thailand
Indonesia
Japan
Others